1. Immunology/Inflammation
  2. STING
    Interleukin Related

DMXAA (Synonyms: ASA-404; Vadimezan)

Cat. No.: HY-10964 Purity: 99.19%
Handling Instructions

DMXAA, the vascular disrupting agent, is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines.

For research use only. We do not sell to patients.

DMXAA Chemical Structure

DMXAA Chemical Structure

CAS No. : 117570-53-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 106 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 96 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 132 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 528 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 840 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

DMXAA, the vascular disrupting agent, is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines.

IC50 & Target

STING[1], type I IFNs[2]

In Vitro

DMXAA, the vascular disrupting agent, is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. DMXAA has no detrimental effect on 344SQ-ELuc cell viability. It is found that DMXAA-mediated up regulation of the NF-κB pathway as shown by increased p65 phosphorylation in M2 macrophages[1]. Results demonstrate that DMXAA-treated cells are protected from VSV-induced cytotoxicity at all MOIs in contrast to medium-pretreated macrophages. DMXAA effectively inhibits growth of both strains of influenza, demonstrating the potential of DMXAA for treatment of drug-resistant strains of human influenza[2].

In Vivo

344SQ-ELuc NSCLC subcutaneous tumors respond dramatically to DMXAA, with a marked decrease in bioluminescence (BLI) signals post-drug injection. DMXAA treatment of 344SQ-ELuc metastases yields no decrease in photon emission rates, with the tumors remaining histologically similar to controls after this treatment. As with the large subcutaneous tumors, DMXAA administration to mice with small subcutaneous tumors still leads to ~2-log decreases in photon emission at both 6 and 24 hours[1]. In vivo, DMXAA is a more potent inducer of IFN-β mRNA and a relatively poor inducer of TNF-α mRNA. DMXAA administration leads to significantly less weight loss in influenza-infected mice[2].

Clinical Trial
References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.5425 mL 17.7123 mL 35.4246 mL
5 mM 0.7085 mL 3.5425 mL 7.0849 mL
10 mM 0.3542 mL 1.7712 mL 3.5425 mL
Please refer to the solubility information to select the appropriate solvent.
Kinase Assay
[1]

M2-polarized macrophages are treated with 20 µg/mL DMXAA or DMSO vehicle for 30 min. Cells are then lysed and protein denatured in SDS buffer and samples sent for RPPA analysis. Differential abundance of various proteins and/or their phosphorylation status in response to DMXAA is assessed[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

RAW 264.7 macrophages are cultured and plated at 1×105 cells/well in a 96-well plate. After overnight incubation at 37°C, cells are treated with medium containing vehicle or DMXAA (100 μg/mL). After 6 h, the culture medium is replaced with serum-free DMEM containing VSV at the indicated MOI for 1 h. Cells are then maintained in complete DMEM with 10% FBS. Twenty-four hours later, cells are washed with PBS, fixed with 10% buffered formalin, and rinsed thoroughly with distilled water. Adherent cells are stained with crystal violet[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Male 129/Sv mice (6 to 12 week old) are used in this study. To generate subcutaneous tumors, 5×105 344SQ-ELuc cells in 100 µL PBS are injected in both posterior flanks of mice. Tumor growth is monitored every 2 to 4 days via BLI. Once tumors are established (day 10 for systemic metastases; day 7 or day 14 for subcutaneous tumors), mice are given 25 mg/kg of DMXAA, or DMSO vehicle by i.p. injection. BLI is carried out at 6 and 24 hours [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

282.29

Formula

C₁₇H₁₄O₄

CAS No.

117570-53-3

SMILES

O=C(O)CC1=CC=CC(C2=O)=C1OC3=C2C=CC(C)=C3C

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 6.5 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DMXAA
Cat. No.:
HY-10964
Quantity: